Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Unapproved Drugs Policy Draws Legal, Regulatory Responses From Lannett, To Little Success

Executive Summary

Generic drug maker Lannett Co. is taking a two-pronged approach in responding to FDA’s unapproved drugs initiative, seeking regulatory approval of a previously unapproved opioid product while simultaneously suing the agency in federal court.
Advertisement

Related Content

FDA Oxycodone Enforcement Built On Difference Between “Same” And “Identical”
Sept. 19, 2011: The Day FDA’s Discretion On Unapproved Drugs Stood Still
Sept. 19, 2011: The Day FDA’s Discretion On Unapproved Drugs Stood Still
Roxane's Redesigned Morphine Carton Reflects Orderly Rollout After Safety Concern
From Beginning To End, FDA Transparency Weighed On Sharfstein’s Mind
From Beginning To End, FDA Transparency Weighed On Sharfstein’s Mind
Roxane's Oral Morphine Sulfate Gets FDA Approval, But Also Inventory Oversight

Topics

Advertisement
UsernamePublicRestriction

Register

PS053036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel